{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:24:33Z","timestamp":1772173473943,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1012999","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000}}],"reference-count":73,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Elegant North","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","award":["DNRF125"],"award-info":[{"award-number":["DNRF125"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009910","name":"Hartmann Fonden","doi-asserted-by":"publisher","award":["R241-A33877"],"award-info":[{"award-number":["R241-A33877"]}],"id":[{"id":"10.13039\/501100009910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012331","name":"LEO Fondet","doi-asserted-by":"publisher","award":["LF17006"],"award-info":[{"award-number":["LF17006"]}],"id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF20OC0065262"],"award-info":[{"award-number":["NNF20OC0065262"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009938","name":"Knud H\u00f8jgaards Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009938","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021851","name":"William Demant Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004209","name":"Otto M\u00f8nsteds Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA260271"],"award-info":[{"award-number":["R01 CA260271"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Cancer involves dynamic changes caused by (epi)genetic alterations such as mutations or abnormal DNA methylation patterns which occur in cancer driver genes. These driver genes are divided into oncogenes and tumor suppressors depending on their function and mechanism of action. Discovering driver genes in different cancer (sub)types is important not only for increasing current understanding of carcinogenesis but also from prognostic and therapeutic perspectives. We have previously developed a framework called Moonlight which uses a systems biology multi-omics approach for prediction of driver genes. Here, we present an important development in Moonlight2 by incorporating a DNA methylation layer which provides epigenetic evidence for deregulated expression profiles of driver genes. To this end, we present a novel functionality called Gene Methylation Analysis (GMA) which investigates abnormal DNA methylation patterns to predict driver genes. This is achieved by integrating the tool EpiMix which is designed to detect such aberrant DNA methylation patterns in a cohort of patients and further couples these patterns with gene expression changes. To showcase GMA, we applied it to three cancer (sub)types (basal-like breast cancer, lung adenocarcinoma, and thyroid carcinoma) where we discovered 33, 190, and 263 epigenetically driven genes, respectively. A subset of these driver genes had prognostic effects with expression levels significantly affecting survival of the patients. Moreover, a subset of the driver genes demonstrated therapeutic potential as drug targets. This study provides a framework for exploring the driving forces behind cancer and provides novel insights into the landscape of three cancer sub(types) by integrating gene expression and methylation data.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1012999","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T13:56:23Z","timestamp":1745243783000},"page":"e1012999","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revealing cancer driver genes through integrative transcriptomic and epigenomic analyses with Moonlight"],"prefix":"10.1371","volume":"21","author":[{"given":"Mona","family":"Nourbakhsh","sequence":"first","affiliation":[]},{"given":"Yuanning","family":"Zheng","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-8122","authenticated-orcid":true,"given":"Humaira","family":"Noor","sequence":"additional","affiliation":[]},{"given":"Hongjin","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Subhayan","family":"Akhuli","sequence":"additional","affiliation":[]},{"given":"Matteo","family":"Tiberti","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9965-5466","authenticated-orcid":true,"given":"Olivier","family":"Gevaert","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7376-5894","authenticated-orcid":true,"given":"Elena","family":"Papaleo","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"3","key":"pcbi.1012999.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7239","key":"pcbi.1012999.ref002","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"MR Stratton","year":"2009","journal-title":"Nature"},{"issue":"6127","key":"pcbi.1012999.ref003","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"B Vogelstein","year":"2013","journal-title":"Science"},{"issue":"3","key":"pcbi.1012999.ref004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41389-018-0034-x","article-title":"Double agents: genes with both oncogenic and tumor-suppressor functions","volume":"7","author":"L Shen","year":"2018","journal-title":"Oncogenesis"},{"issue":"1","key":"pcbi.1012999.ref005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cells10010046","article-title":"Tumor suppressors having oncogenic functions: the double agents","volume":"10","author":"N Datta","year":"2020","journal-title":"Cells"},{"key":"pcbi.1012999.ref006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"D Hanahan","year":"2000","journal-title":"Cell"},{"issue":"5","key":"pcbi.1012999.ref007","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"D Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"pcbi.1012999.ref008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"D Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"pcbi.1012999.ref009","doi-asserted-by":"crossref","first-page":"bbad519","DOI":"10.1093\/bib\/bbad519","article-title":"Prediction of cancer driver genes and mutations: the potential of integrative computational frameworks","volume":"25","author":"M Nourbakhsh","year":"2024","journal-title":"Brief Bioinform"},{"issue":"8","key":"pcbi.1012999.ref010","doi-asserted-by":"crossref","first-page":"112978","DOI":"10.1016\/j.celrep.2023.112978","article-title":"Genome-guided discovery of cancer therapeutic targets","volume":"42","author":"P Konda","year":"2023","journal-title":"Cell Rep"},{"issue":"12","key":"pcbi.1012999.ref011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/bies.201500093","article-title":"Targeting tumor suppressor genes for cancer therapy","volume":"37","author":"Y Liu","year":"2015","journal-title":"Bioessays"},{"issue":"1","key":"pcbi.1012999.ref012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"X Yu","year":"2024","journal-title":"Cell Death Discov"},{"issue":"D1","key":"pcbi.1012999.ref013","doi-asserted-by":"crossref","first-page":"D416","DOI":"10.1093\/nar\/gkz871","article-title":"CancerGeneNet: linking driver genes to cancer hallmarks","volume":"48","author":"M Iannuccelli","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pcbi.1012999.ref014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41467-019-13803-0","article-title":"Interpreting pathways to discover cancer driver genes with Moonlight","volume":"11","author":"A Colaprico","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"pcbi.1012999.ref015","doi-asserted-by":"crossref","first-page":"bbad274","DOI":"10.1093\/bib\/bbad274","article-title":"A workflow to study mechanistic indicators for driver gene prediction with Moonlight","volume":"24","author":"M Nourbakhsh","year":"2023","journal-title":"Brief Bioinform"},{"issue":"10","key":"pcbi.1012999.ref016","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers","volume":"45","author":"G Ciriello","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"pcbi.1012999.ref017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/epi.09.33","article-title":"DNA hypomethylation in cancer cells","volume":"1","author":"M Ehrlich","year":"2009","journal-title":"Epigenomics"},{"issue":"11","key":"pcbi.1012999.ref018","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"M Esteller","year":"2008","journal-title":"N Engl J Med"},{"key":"pcbi.1012999.ref019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-319-43624-1_7","article-title":"The role of DNA methylation in cancer","volume":"945","author":"R Lakshminarasimhan","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"pcbi.1012999.ref020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.18632\/oncoscience.42","article-title":"Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation","volume":"1","author":"S S\u00f8es","year":"2014","journal-title":"Oncoscience"},{"issue":"7","key":"pcbi.1012999.ref021","doi-asserted-by":"crossref","first-page":"100515","DOI":"10.1016\/j.crmeth.2023.100515","article-title":"EpiMix is an integrative tool for epigenomic subtyping using DNA methylation","volume":"3","author":"Y Zheng","year":"2023","journal-title":"Cell Rep Methods"},{"issue":"1A","key":"pcbi.1012999.ref022","first-page":"A68-77","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge","volume":"19","author":"K Tomczak","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"issue":"2","key":"pcbi.1012999.ref023","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cell.2018.03.042","article-title":"The Cancer Genome Atlas: creating lasting value beyond its data","volume":"173","author":"C Hutter","year":"2018","journal-title":"Cell"},{"issue":"1","key":"pcbi.1012999.ref024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"LD Moore","year":"2013","journal-title":"Neuropsychopharmacol"},{"issue":"11","key":"pcbi.1012999.ref025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","article-title":"The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers","volume":"18","author":"Z Sondka","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"pcbi.1012999.ref026","doi-asserted-by":"crossref","first-page":"103362","DOI":"10.1016\/j.compbiomed.2019.103362","article-title":"Cancer driver gene discovery in transcriptional regulatory networks using influence maximization approach","volume":"114","author":"M Rahimi","year":"2019","journal-title":"Comput Biol Med"},{"key":"pcbi.1012999.ref027","doi-asserted-by":"crossref","first-page":"104326","DOI":"10.1016\/j.biosystems.2020.104326","article-title":"KatzDriver: a network based method to cancer causal genes discovery in gene regulatory network","volume":"201","author":"M Akhavan-Safar","year":"2021","journal-title":"Biosystems"},{"key":"pcbi.1012999.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/4826206","article-title":"DriverFinder: a gene length-based network method to identify cancer driver genes","author":"P-J Wei","year":"2017","journal-title":"Complexity"},{"issue":"12","key":"pcbi.1012999.ref029","doi-asserted-by":"crossref","first-page":"e1007538","DOI":"10.1371\/journal.pcbi.1007538","article-title":"CBNA: A control theory based method for identifying coding and non-coding cancer drivers","volume":"15","author":"VVH Pham","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"pcbi.1012999.ref030","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/bioinformatics\/btz815","article-title":"PRODIGY: personalized prioritization of driver genes","volume":"36","author":"G Dinstag","year":"2020","journal-title":"Bioinformatics"},{"issue":"Suppl 17","key":"pcbi.1012999.ref031","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12859-016-1332-y","article-title":"LNDriver: identifying driver genes by integrating mutation and expression data based on gene-gene interaction network","volume":"17","author":"P-J Wei","year":"2016","journal-title":"BMC Bioinform"},{"key":"pcbi.1012999.ref032","doi-asserted-by":"crossref","first-page":"607798","DOI":"10.3389\/fgene.2020.607798","article-title":"DriverSubNet: a novel algorithm for identifying cancer driver genes by subnetwork enrichment analysis","volume":"11","author":"D Zhang","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"pcbi.1012999.ref033","doi-asserted-by":"crossref","first-page":"16904","DOI":"10.1038\/s41598-019-52886-z","article-title":"Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis","volume":"9","author":"A Li","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"pcbi.1012999.ref034","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/gkz096","article-title":"DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies","volume":"47","author":"Y Han","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1012999.ref035","doi-asserted-by":"crossref","first-page":"564839","DOI":"10.3389\/fgene.2020.564839","article-title":"FI-Net: identification of cancer driver genes by using functional impact prediction neural network","volume":"11","author":"H Gu","year":"2020","journal-title":"Front Genet"},{"issue":"9","key":"pcbi.1012999.ref036","doi-asserted-by":"crossref","first-page":"1800640","DOI":"10.1002\/advs.201800640","article-title":"MaxMIF: a new method for identifying cancer driver genes through effective data integration","volume":"5","author":"Y Hou","year":"2018","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"pcbi.1012999.ref037","doi-asserted-by":"crossref","first-page":"13124","DOI":"10.1038\/s41598-017-12888-1","article-title":"Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes","volume":"7","author":"L Zapata","year":"2017","journal-title":"Sci Rep"},{"issue":"7986","key":"pcbi.1012999.ref038","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-023-06682-5","article-title":"Epigenetic regulation during cancer transitions across 11 tumour types","volume":"623","author":"NV Terekhanova","year":"2023","journal-title":"Nature"},{"key":"pcbi.1012999.ref039","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/1476-4598-9-300","article-title":"Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells","volume":"9","author":"L D\u2019Anello","year":"2010","journal-title":"Mol Cancer"},{"issue":"1","key":"pcbi.1012999.ref040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-020-00632-3","article-title":"Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-\u03b2 signaling","volume":"27","author":"Y-T Lin","year":"2020","journal-title":"J Biomed Sci"},{"issue":"12","key":"pcbi.1012999.ref041","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.tig.2017.08.004","article-title":"Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity","volume":"33","author":"N Skrypek","year":"2017","journal-title":"Trends Genet"},{"key":"pcbi.1012999.ref042","doi-asserted-by":"crossref","first-page":"657546","DOI":"10.3389\/fonc.2021.657546","article-title":"Epigenetic regulation of epithelial to mesenchymal transition in the cancer metastatic cascade: implications for cancer therapy","volume":"11","author":"Q-L Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"pcbi.1012999.ref043","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","article-title":"Epithelial-mesenchymal plasticity in cancer progression and metastasis","volume":"49","author":"W Lu","year":"2019","journal-title":"Dev Cell"},{"issue":"1","key":"pcbi.1012999.ref044","doi-asserted-by":"crossref","first-page":"bbac528","DOI":"10.1093\/bib\/bbac528","article-title":"From multi-omics data to the cancer druggable gene discovery: a novel machine learning-based approach","volume":"24","author":"H Yang","year":"2023","journal-title":"Brief Bioinform"},{"issue":"9","key":"pcbi.1012999.ref045","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s10038-021-00962-6","article-title":"Functional genomics for breast cancer drug target discovery","volume":"66","author":"T Yoshimaru","year":"2021","journal-title":"J Hum Genet"},{"issue":"51","key":"pcbi.1012999.ref046","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.18632\/oncotarget.26985","article-title":"Targeted drug combination therapy design based on driver genes","volume":"10","author":"L Zs\u00e1kai","year":"2019","journal-title":"Oncotarget"},{"issue":"D1","key":"pcbi.1012999.ref047","doi-asserted-by":"crossref","first-page":"D1227","DOI":"10.1093\/nar\/gkad1040","article-title":"DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms","volume":"52","author":"M Cannon","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"pcbi.1012999.ref048","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/sj.bjc.6604344","article-title":"Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel\/gemcitabine","volume":"98","author":"J Souglakos","year":"2008","journal-title":"Br J Cancer"},{"issue":"2","key":"pcbi.1012999.ref049","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41417-022-00541-7","article-title":"Sorting nexin-dependent therapeutic targeting of oncogenic epidermal growth factor receptor","volume":"30","author":"B Atwell","year":"2023","journal-title":"Cancer Gene Ther"},{"issue":"7878","key":"pcbi.1012999.ref050","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"JP Robichaux","year":"2021","journal-title":"Nature"},{"issue":"5","key":"pcbi.1012999.ref051","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"JP Robichaux","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"pcbi.1012999.ref052","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"P Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pcbi.1012999.ref053","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41467-021-23912-4","article-title":"Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I\/II trial in advanced EGFR-mutant non-small cell lung cancer","volume":"12","author":"KE Poels","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1012999.ref054","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41467-022-34398-z","article-title":"Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations","volume":"13","author":"IK van Alderwerelt van Rosenburgh","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1012999.ref055","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1186\/s12885-023-11465-2","article-title":"Efficacy and safety of dacomitinib in treatment-na\u00efve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study","volume":"23","author":"X Pu","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"pcbi.1012999.ref056","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1038\/s41598-017-04147-0","article-title":"Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells","volume":"7","author":"M Momeny","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"pcbi.1012999.ref057","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"K Brischwein","year":"2006","journal-title":"Mol Immunol"},{"key":"pcbi.1012999.ref058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13046-015-0241-7","article-title":"Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE\u00ae), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro","volume":"34","author":"F Ferrari","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"pcbi.1012999.ref059","doi-asserted-by":"crossref","first-page":"165","DOI":"10.15698\/cst2019.06.188","article-title":"Biology and clinical relevance of EpCAM","volume":"3","author":"L Keller","year":"2019","journal-title":"Cell Stress"},{"issue":"17","key":"pcbi.1012999.ref060","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.3390\/cancers14174121","article-title":"Dynamic expression of EpCAM in primary and metastatic lung cancer is controlled by both genetic and epigenetic mechanisms","volume":"14","author":"Y Cui","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pcbi.1012999.ref061","doi-asserted-by":"crossref","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"M Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"issue":"7132","key":"pcbi.1012999.ref062","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"C Greenman","year":"2007","journal-title":"Nature"},{"issue":"1","key":"pcbi.1012999.ref063","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"ZR Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"10","key":"pcbi.1012999.ref064","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/09553002.2020.1793015","article-title":"NRP1 regulates radiation-induced EMT via TGF-\u03b2\/Smad signaling in lung adenocarcinoma cells","volume":"96","author":"Z Chen","year":"2020","journal-title":"Int J Radiat Biol"},{"issue":"15","key":"pcbi.1012999.ref065","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in breast cancer progression, diagnosis, and treatment","volume":"11","author":"CO Madu","year":"2020","journal-title":"J Cancer"},{"issue":"1","key":"pcbi.1012999.ref066","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment","volume":"9","author":"RI Teleanu","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"pcbi.1012999.ref067","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/cbf.3663","article-title":"Angiogenesis induction in breast cancer: a paracrine paradigm","volume":"39","author":"N Badodekar","year":"2021","journal-title":"Cell Biochem Funct"},{"issue":"6","key":"pcbi.1012999.ref068","first-page":"1188","article-title":"Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma","volume":"144","author":"RK Vartanian","year":"1994","journal-title":"Am J Pathol"},{"issue":"1","key":"pcbi.1012999.ref069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199101033240101","article-title":"Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma","volume":"324","author":"N Weidner","year":"1991","journal-title":"N Engl J Med"},{"issue":"15","key":"pcbi.1012999.ref070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells12152014","article-title":"Implication of mTOR signaling in NSCLC: mechanisms and therapeutic perspectives","volume":"12","author":"AN Gargalionis","year":"2023","journal-title":"Cells"},{"issue":"7","key":"pcbi.1012999.ref071","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/hmg\/10.7.699","article-title":"The Rb\/E2F pathway and cancer","volume":"10","author":"JR Nevins","year":"2001","journal-title":"Hum Mol Genet"},{"key":"pcbi.1012999.ref072","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"LN Kent","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"pcbi.1012999.ref073","doi-asserted-by":"crossref","first-page":"051","DOI":"10.1385\/1-59259-788-2:051","volume-title":"Analyzing the G2\/M Checkpoint. Checkpoint controls and cancer","author":"GR Stark","year":"2004"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1012999","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T16:26:18Z","timestamp":1746635178000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012999"}},"subtitle":[],"editor":[{"given":"Hatice Ulku","family":"Osmanbeyoglu","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1012999","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.14.584946","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}